CMS’s Proposed PBM Rule Puts Payment Details on the Table
CMS proposed new Medicare Part D rules on October 16 aimed at making pharmacy benefit managers (PBMs) explain more of their compensation and contractual arrangements. The proposal raises a useful invoice question: who pays the PBM, and what service is that payment buying? In health care, the answer can arrive dressed as a spreadsheet wearing a fake mustache.
More detail for plan sponsors
Under the proposal, PBMs would provide annual reporting on their compensation and cost performance in Part D. CMS also proposes greater transparency around price guarantees and disclosure to plan sponsors of certain terms in agreements between PBMs and drug manufacturers. Those details could help sponsors assess what they are paying for and how the arrangement is performing.
That information would not automatically become public. The proposal focuses on reporting and disclosures for plan sponsors, giving them more material to examine; it is not a promise that every contract term or payment detail will be posted for everyone to see. More paperwork in the hands of the people managing a plan may improve their ability to scrutinize an arrangement, but it does not guarantee what they will conclude or do with it.
The proposal also addresses how PBMs are compensated, with limits tying certain compensation to the fair market value of services rather than to drug costs. The distinction matters: a fee linked to a drug’s price can create a different incentive from a fee tied to a defined service. CMS’s proposal aims to make the relationship easier to inspect. Its practical effect would depend on the final requirements and how plan sponsors use the information.
Transparency is not a discount coupon
CMS says the proposal implements provisions in the 2026 Consolidated Appropriations Act. The agency’s fact sheet describes reporting, price-guarantee transparency, manufacturer-agreement disclosures and compliance requirements. But a proposal is not a receipt showing that a patient’s next prescription will cost less. The proposed disclosures do not establish that premiums or out-of-pocket costs will fall. Better information may help plan sponsors evaluate contracts; whether that changes what patients pay remains an open question.
That is the useful distinction for patients and taxpayers: the policy is aimed at making payment arrangements easier for plan sponsors to examine, not announcing a price cut. A sponsor getting a clearer view of compensation and contract terms is a step toward accountability. It is not the same as savings reaching the pharmacy counter. Follow the invoice, then check whether the benefit made it past the conference room.
Still a proposal
The Federal Register inspection copy schedules publication for October 20, 2026, and lists December 15, 2026, as the deadline for comments. The rule is proposed, not final or already in effect. For now, CMS has put additional PBM payment and contract information on the table for plan sponsors to examine. The next test is whether clearer paperwork produces better oversight—and whether any gains eventually reach the people paying for prescriptions.